RxDoctor Payments Data

Glen Owen

Optometrist · Edmonds, WANPI 1174613715

Payments from drug & device makers

$1,535in general payments, 2019–2025

Across 25 payments — averaging $61.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$568
  • Carl Zeiss Meditec USA, Inc.$254
  • Alcon$248
  • Glaukos Corporation$169
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$128
  • AbbVie$87
  • plus $82 from 2 others

What the payments were for

  • Food & beverage$1,535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,535 in reported general payments places this provider in the 75th percentile of 1,267 optometrist providers in Washington.

See all optometrist providers in Washington

Medicare billing

Part B allowed, 2024
$87,511
Medicare patients
293
Services billed
1,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost94$43,994
RestasisCyclosporine18$26,680
LumiganBimatoprost24$8,500
Travoprost48$7,214
Latanoprost560$6,188
SimbrinzaBrinzolamide/Brimonidine Tart12$5,387
Timolol MaleateTimolol Maleate/Pf11$3,322
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat115$1,798
Betaxolol Hcl19$1,644
Fluorometholone19$1,420
Tobramycin-DexamethasoneTobramycin/Dexamethasone25$1,227
Prednisolone Acetate20$884
Dorzolamide Hcl47$752
Timolol Maleate60$404
Minocycline Hcl23$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$87$35,18042 claims
AlconSimbrinza$248$5,38712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,267 optometrist providers in Washington.

Other optometrist in Edmonds

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →